четверг, 18 февраля 2016 г.

Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator

Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator


Currently it is just the warning letter that is at the top of everybody's mind when it comes to investing in Dr. Reddy. By 2022, Proprietary product business alone should contribute about INR 70 per share to the EPS.



from Biotech News